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miRNAs are a class of small-noncoding RNAs capable of negatively regulating gene expression. Here,
we found that miR-195 is down-regulated in human bladder cancer tissue versus normal adjacent
tissue. To better characterize the role of miR-195 in bladder cancer, we conducted gain of function
analysis by transfecting bladder cancer cell line T24 with chemically synthesized miR-195 mimic.
We identiﬁed CDK4, an early G1 cell cycle regulator, as a novel target of miR-195. Selective over-
expression of miR-195 could induce G1-phase arrest in T24 cells, and subsequently inhibit T24 cell
growth. These ﬁndings indicate that miR-195 could be a potential tumor suppressor in bladder
cancer.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Urinary bladder cancer ranks nineth in worldwide cancer inci-
dence [1], and it has been listed as the most common genitourinary
tract malignancy in China [2]. It is believed that tumorigenesis and
progression of bladder cancer would involve various genetic
changes, such as chromosomal anomalies, genetic polymorphisms,
genetic and epigenetic alterations [3]. However, the exact mecha-
nisms of bladder tumorigenesis are still not well understood.
Understanding these genetic alterations is crucial to identify novel
prognostic biomarkers and therapeutic targets.
MicroRNAs (miRNAs) are small (22 nucleotides), endogenous,
noncoding RNAs, which make up a novel class of gene regulators
[4]. They induce post-transcriptional gene repression by blocking
the translation and/or accelerating the degradation of their target
mRNAs, and are thus involved in diverse cellular processes, such
as differentiation, proliferation, metabolism and apoptosis [5].
Recently, a large amount of studies have been published to illus-
trate the association between speciﬁc miRNA function and carcino-
genesis [6,7]. Meanwhile, accumulating evidences indicate thatchemical Societies. Published by E
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2577.aberrant expression of miRNAs can contribute to bladder tumori-
genesis. Gottardo et al. [8] ﬁrstly investigated miRNA expression
pattern in bladder cancer in 2007. They reported ten up-regulated
miRNAs (miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-
23b, miR-203, miR-17-5p, miR-23a and miR-205) in 25 urothelial
tumor samples compared with 2 normal bladder mucosa. In the
microarray study by Lin et al. [9], bladder cancer presented with
a signiﬁcant lower expression of miR-143, miR-145, miR-125 and
miR-199b compared with normal adjacent tissues. They also vali-
dated that miR-143 could function as tumor suppressor by target-
ing oncogene ras. Ostenfeld et al. [10] conﬁrmed the down-
regulation of miR-145 in bladder cancer tissue by ISH analysis
and found that ectopic expression of miR-145 induced extensive
apoptosis in urothelial carcinoma cell lines. In the bladder cancer
miRNA signature analysis by Ichimi et al. [11], a set of aberrantly
expressed miRNAs were identiﬁed, including miR-195, which pre-
sented with proximately 80% reduction in expression level in can-
cer tissue. A similar down-regulated pattern of miR-195 in bladder
cancer was also observed in the genome-wide miRNA expression
pattern’s study by Han et al. [12].
miR-195 exhibits diverse expression pattern and function dif-
ferently in different cancer [13–17]. It was reported that miR-195
could inhibit hepatocellular carcinoma cell proliferation by target-
ing Cyclin D1, CDK6, and E2F3 [16] and promote colorectal cancer
cell apoptosis by repressing Bcl-2 [17]. However, the biological
function of miR-195 in bladder cancer was not well established.
In our present works, we further veriﬁed miR-195 expressionlsevier B.V. All rights reserved.
Table 1
The oligonucleotides used in this study.
Namea Sequence(50->30)b













a F, forward primer; R, reverse primer.
b Restriction sites are in bold; Mutated sites are underlined.
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that miR-195 could suppress growth of the human bladder cancer
cell line T24. The tumor suppressive role and regulatory mecha-
nisms of miR-195 on bladder cancer were determined.
2. Materials and methods
2.1. Reagents
miR-195 mimic (shortly named as miR-195) and FAM-conju-
gated negative control duplex (named as NC) lacking signiﬁcant
homology to all known human sequences were applied for tran-
sient gain of function study. For the in vivo and in vitro tumorige-
nicity assay, the duplexes with 20-O-methyl modiﬁcation were
used. The small interference RNA targeting human CDK4 mRNA
(designated as siCDK4) was designed as described before [18],
which targeted nucleotides 1062–1082 according to Genbank
accession NM_000075. All the RNA duplexes were chemically syn-
thesized by GenePharma (Shanghai, China). The sequences were
listed in Table 1.
2.2. Tissue samples
Paired bladder cancer tissues and adjacent non-tumorous blad-
der mucosal tissues were obtained from patients undergoing radi-
cal cystectomy. The samples were collected between Jan 2011 and
June 2011 at the First Afﬁliated Hospital of Medical College,
Zhejiang University (Hangzhou, P.R. China) after informed consent
and Ethics Committee’s approval. The demographic and cancer
staging data was listed in Table s1. Tissue samples were trimmed
and snap frozen in liquid nitrogen until use.
2.3. Cell culture and transfection
The human bladder cancer cell line T24 (Shanghai Institute of
Cell Biology, Chinese Academy of Sciences) was cultured in RPMI
1640 medium supplemented with 10% heat-inactivated fetal bo-
vine serum, penicillin (50 U/ml), and streptomycin (50 lg/ml) in
a humidiﬁed atmosphere containing 5% CO2 maintained at 37 C.
The day before transfection cells were plated to 60–70% conﬂuency
in medium without antibiotics. The transfection was performed
using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA)
following the manufacturer’s instructions and the transfection efﬁ-
ciency was monitored by FAM-conjugated NC.
2.4. RNA isolation and real-time PCR
Small RNA was isolated from frozen samples by using RNAiso
for Small RNA (TaKaRa, Japan) and reverse transcribed using One
Step PrimeScript miRNA cDNA Synthesis Kit (TaKaRa, Japan), while
total RNA from transfected T24 cells was extracted with RNAiso
plus (TaKaRa, Japan) and transcribed into cDNA with PrimeScript
RT reagent Kit (TaKaRa, Japan). The resulting cDNA was quantiﬁed
by real-time RT-PCR using SYBR Premix Ex Taq (TaKaRa, Japan).
The relative expression level of miR-195 and CDK4 was calculated
and quantiﬁed with the 2DDCt method after normalization with
reference to expression of U6 small nuclear RNA and GAPDH,
respectively. All the primers were listed in Table 1.
2.5. Cell growth/cell viability assay
Cells were seeded in 96-well plate at a density of 4  103/well.
After overnight incubation, the cells were treatedwith RNA duplexes
(5–100 nM) for 48–72 h. After incubated for indicated time, cell-
counting solution (WST-8, Dojindo Laboratories, Tokyo, Japan)was added to each well and incubated for an additional 2 h. The
absorbance of the solution was measured spectrophotometrically
at 450 nm with MRX II absorbance reader (Dynex Technologies,
Chantilly, VA, USA).
2.6. In vitro colony formation assay
Twenty-four hours after transfection with 20-O-Methyl modiﬁed
duplexes (50 nM), cells were harvest. Five hundreds of transfected
cells were seeded in a fresh six-well and kept in culture undisturbed
for 10 days, during which time the surviving cells spawned a colony
of proliferating cells. Colony formationwas analyzed by staining the
cellswith 0.1% crystal violet. The rate of colony formationwas calcu-
latedwith the following equation: colony formation rate = (number
of colonies/number of seeded cells)  100%.
2.7. In vivo tumorigenicity assays
Animal study was performed according to institutional guide-
lines. Male BALB/c-nude mice aged 4 weeks were used for human
tumor xenograft model (supplied by the Shanghai Experimental
Animal Center, Chinese Academy of Sciences, Shanghai, China).
The mice were injected s.c. with either NC or miR-195 transfected
cells (5  107 in 50 ll PBS). Tumor size was monitored and evalu-
ated every 3 days. When the tumor became palpable, the tumor
growth curves were depicted. The volume of the tumor was calcu-
lated from the formula length width2  0.52 [19], where length
and width were tumor diameters measured with calipers in mutu-
ally perpendicular directions.
2.8. Cell cycle analysis by ﬂow cytometry
Cells were harvested 48 following transfection, washed with
PBS and ﬁxed in 75% ethanol at 20 C. After overnight ﬁxation,
cells were washed with PBS and stained with DNA Prep Stain
(Beckman Coulter, Fullerton, CA) for 30 min. Cell cycle analysis
was performed by BD LSRII Flow Cytometry System with FACSDiva
software (BD Bioscience, Franklin Lakes, USA). The cell cycle distri-
bution was presented as the percentage of cells in G1, S, and G2
populations. Data was analyzed with ModFit LT software package.
2.9. Western blotting analysis
Brieﬂy, cellswereharvestedat48 h followingoligo treatmentasde-
scribed above, lysed and quantiﬁed. Equivalent quantities (30–50 lg)
of protein were separated by 10% SDS-polyacrylamide gels and trans-
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non-fat milk and then incubated overnight with the appropriate pri-
mary antibody at dilutions speciﬁed by the manufacturer. They were
next washed three times in 15ml TBS-Tween and incubated with the
corresponding horseradish peroxidase (HRP)-conjugated secondary
antibody at 1:2500 dilution in TBS-Tween for 1 h. Bound secondary
antibody was detected using an enhanced chemiluminescence (ECL)
system (Pierce Biotechnology Inc., Rockford, IL). Primary immunoblot-
ting antibodies were: anti-b-actin, anti-phosphorylated Rb (S795),
anti-phosphorylated Rb (S780) (Cell Signaling Technology, Beverly,
MA), anti-CDK4, anti-CDK6, anti-Cyclin D1(Epitomics, Burlingame,
CA) and anti-E2F3 (Santa-Cruz Biotechnology, Santa Cruz, CA).
2.10. Luciferase assays
To construct the luciferase reporter vectors, the 30-UTR
(untranslated region) of CDK4, which contained putative binding
sites for miR-195, was ampliﬁed from genomic DNA (primer set
in Table 1). The ampliﬁed fragment was inserted into pmirGLO
Dual-Luciferase miRNA Target Expression Vector (Promega, USA)
between the SacI and SalI sites. In addition, mutant 30-UTR, which
carried a mutated sequence in the seeding region of miR-195, was
mutated (primer set in Table 1) within pMD-18 T vector (TaKaRa,
Japan) by the MutanBest Kit (TaKaRa, Japan) and then subcloned
into pmirGLO Dual-Luciferase Vector. Both insertions were veriﬁed
by sequencing. T24 cells plated in a 24-well plate were cotrans-
fected with 50 nM of either miR-195 mimic or negative control
oligo and 200 ng reporter comprising wildtype or mutant 30-UTR.
The relative luciferase activity was measured by Dual-Luciferase
Reporter Assay System (Promega, USA) 48 h after transfection.
2.11. Statistical analysis
Data were expressed as mean ± standard deviation (SD) of three
independent experiments. All analyses were performed using
GraphPad Prism version 5 for Windows and P < 0.05 was consid-
ered to be statistically signiﬁcant with either the student’s t-test
or Two-way ANOVA.
3. Results
3.1. miR-195 is down-regulated in bladder cancer
To determine the expression pattern of miR-195 in human blad-
der cancer, we quantiﬁed the expression levels of miR-195 in 12
pairs of human bladder cancer tissues and adjacent normalmucosal
tissues by real-time RT-PCR.We found thatmiR-195 expression lev-
els were generally lower in cancerous tissues comparing with their
non-cancerous counterparts with exception of 1 pairs (Fig. 1). Fur-
thermore, 7 out of 11 exhibited 50% reduction (Fig. 1A). This was
consistent with fold change data from previous deep sequencing
analysis [12]. Thus, we speculated thatmiR-195might be a putative
tumor suppressor in bladder cancer.
3.2. miR-195 suppresses bladder cancer cell proliferation, and inhibits
clonogenicity both in vitro and in vivo
To elucidate that whether miR-195 could function as a tumor
suppressor, the effects of miR-195 over-expression was evaluated
in vitro with cell growth/cell viability assay. Notably, miR-195
demonstrated a potent inhibitory effect in a dose-dependent man-
ner with a maximal inhibition at about 50 nM (Fig. 2A). miR-195 at
a concentration of 50 nM could reduce cell viability by 29% and
39%, respectively, at 48 or 72 h after transfection. In parallel,
miR-195 also dramatically impaired the colony forming ability ofbladder cancer cells. The colony formation capability of miR-195
transfected cells was much lower than those transfected with NC
(Fig. 2B). To further conﬁrm the above ﬁndings, the tumor growths
of T24 cells with or without miR-195 over-expression were exam-
ined after s.c. implantation into BALB/c mice. Over-expression of
miR-195 resulted in dramatic retardation of tumor initiation and
growth in vivo. In contrast, tumors in miR-195 group presented
with a much slower growth pattern. (Fig. 2C). Taken together,
these results showed that miR-195 negatively modulate bladder
cancer cells growth.
3.3. miR-195 triggers G1-phase arrest via down-regulation of CDK4
The underlying mechanisms for miR-195-suppressed tumor
growth were further explored with FACS. We transfected the T24
cells with 50 nM miR-195 and assessed the impact of miR-195 on
cell cycle distribution 48 h after transfection. The results indicated
that miR-195 could induce G1-phase arrest (Fig. 3A). Consistent
with the cell cycle arrest phenomenon, it also presented with nota-
ble change in the content of positive G1/S transition regulators,
including CDK6, cyclin D1 and E2F3, after 50 nMmiR-195 treatment
(Fig. 4). Beside all these previously validated miR-195’s targets[16],
CDK4, a novel putative target ofmiR-195 after integrating data from
targets prediction from MicroCosm Targets (http://www.ebi.ac.uk/
enright-srv/microcosm/htdocs/targets/v5/) and targeting genes
from themiRTarBase (http://mirtarbase.mbc.nctu.edu.tw), was sig-
niﬁcantly decreased in both mRNA and protein level (Fig. 5). As a
possible novel target of miR-195, the physiological function of
CDK4 was further evaluated via RNAi approach. The knock-down
of CDK4yielded the anticipated cell cycle arrest,which phenocopied
the effect ofmiR-195over-expression (Fig. 3B). To further character-
ize the cell cycle arrest, the CDK4 speciﬁc Rb phosphorylation status
was analyzed. Consistent with the G1-phase arrest, the phosphory-
lation of Rb on Ser780 and Ser795 was attenuated after either miR-
195 or siCDK4 treatment (Fig. 5).
3.4. CDK4 is a novel direct target of miR-195
We next investigated whether CDK4 was a direct functional tar-
get ofmiR-195. The 3’-UTRof CDK4was cloned into down-streamof
ﬁreﬂy luciferase of pmirGLO Dual-Luciferase miRNA Target Expres-
sion Vector. Additional vector with mutated putative binding sites
was also constructed (Fig. 6A). Cotransfected of either miR-195 or
NC and reporter comprising wildtype (Wt) or mutant (Mut) 3’-UTR
was performed. T24 cells transiently transfected with the Wt-3’-
UTR-reporter and miR-195 exhibited signiﬁcantly decreased rela-
tive luciferase activity when comparedwith NC. However, the lucif-
erase activity of the reporter carrying 3’-UTR with mutated binding
sites was unaffected by a simultaneous transfection of miR-195
(Fig. 6B). These ﬁndings indicated that miR-195 inhibited CDK4
expression through direct binding of 3’-UTR of its transcript.
4. Discussion
It is generally believed that there is an urgent need to develop
effective targeted therapeutic strategy leading to improve of sur-
vival outcome of patients with bladder cancer [20]. Thus, identiﬁ-
cation of the molecular pathogenesis of bladder is crucial. Recently,
an increasing number of studies have demonstrated that deregula-
tion of miRNAs was a common events in tumor tissues [6,21].
Experimental evidences have shown that miRNAs would be ideal
tumor biomarkers or therapeutic targets [22,23]. Previous system-
atic review [24] have summarized that the deregulated miRNAs is
common in bladder cancer. A number of studies [8,9,11,12,25,26]
have created signatures for bladder cancer, which will help further
Fig. 1. Quantitative analysis of miR-195 in urinary bladder cancer tissues. The expression of miR-195 was normalized with U6 snRNA in real-time RT-PCR analysis. (A) The
relative expression levels of miR-195 in individual 12 pairs of cancer tissue were presented as the fold change of miR-195 referred to the corresponding normal tissues. (B)
The combined results were shown in a box and whiskers style. Box-plot lines represented medians and interquartile ranges of the normalized threshold values, and whiskers
indicated10–90th percentiles. The expression level of miR-195 was signiﬁcantly lower in cancer tissues (⁄P < 0.05).
Fig. 2. Over-expression of miR-195 suppresses T24 cell growth and tumorigenicity. (A) Cell growth/cell viability assay. The relative cell viability of the miR-195 transfected
group was lower than that of NC transfected (regarded as 1.0). miR-195 reduced the cell viability in dose- and time- dependent manner (Two-way ANOVA, ⁄P < 0.05). (B)
Colony formation assay (Representative wells were presented). The colony formation rate was signiﬁcantly lower for miR-195 treated group compared with NC treated group
(⁄P < 0.05). (C) The effect of miR-195 on tumorigenicity in nude mice. T24 cells treated with NC or miR-195 were inoculated subcutaneously into BALB/C mice. Xenograft
tumors’ volume were assessed every three days. The growth curves indicated that tumor in miR-195 group was in a signiﬁcant slower growth pattern (Two-way ANOVA,
⁄P < 0.05).
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NAs. However, limited studies have explored the modulatory func-
tion of miRNAs in bladder cancer. The roles of speciﬁc miRNAs in
bladder are still poor understood.
Here, we revealed a decrease in expression of the newly identi-
ﬁed tumor suppressive miR-195 in human bladder cancer tissue
compared with normal adjacent tissues. Recently, studies have
shown that miR-195 would be in a controversial expression pat-
tern in different types of cancer [13–17]. However, in majority of
cancers, down-regulation of miR-195 has been observed, such as
prostate cancer [13], hepatic cellular carcinoma [16], colorectal
cancer [17], squamous cell cancer of tongue [15]. Previous miRNA
signature studies have also shown that miR-195 was down-regu-
lated in bladder cancer [11,12]. Our quantiﬁcation analysis yielded
a similar expression pattern. But an additional issue still should be
addressed when interpreting our results. Since our quantiﬁcationdata was from a set of high risk patients who subjected to radical
cystectomy, the down-regulated pattern of miR-195 in bladder
cancer would be probably more common in muscle-invasive or
recurrent disease according to our data.
Furthermore, we validated the functional roles of miR-195 in
bladder cancer cell line T24 by gain of function study. By transfect-
ing T24 cells with miR-195 mimic, we revealed that miR-195 was a
potential tumor suppressor for bladder cancer. Both cell viability
assay and tumorigenicity assay demonstrated that selective over-
expression of miR-195 could inhibit T24 cell growth. Moreover,
FACS analysis suggested that miR-195 could disturb the cell cycle
by inducing G1-phase arrest. In the target screen study, we identi-
ﬁed a novel target of miR-195, CDK4. This ﬁndings was inconsis-
tent with previous study by Sekiya et al. [27], most likely it was
because of the difference in cell types. Our results from phenotypic
analyses indicated that forced expression of miR-195 in T24 cells
Fig. 3. Cell cycle distribution of T24 cells at 48 h after treatment with miR-195 or siCDK4 (Representative histogram are shown above. The indicated percentages are the
average of triplicate experiments). Forty-eight hours after transfection, cells were subjected to ﬂow cytometry. (A) Over-expression of miR-195 induced a signiﬁcant
accumulation of cells in G1-phase and blocks G1-S entry. (B) CDK4 knock-down by siCDK4 induced signiﬁcant G1-phase arrest of up to 25% in T24 cells. (⁄P < 0.05)
Fig. 4. Western blot analysis of G1/S transition regulators (previously validated as
miR-195 targets). b-actin was also blotted and served as a normalizer. CDK6, cyclin
D1 and E2F3 were suppressed by miR-195 over expression.
Fig. 5. The effect of ectopic expression of miR-195 on CDK4 expression and down-stream
mRNA level of CDK4 was signiﬁcantly decreased after miR-195 treatment (⁄P < 0.05). (B)
also blotted and served as a normalizer. CDK4 was suppressed by miR-195 over-expre
Ser795 was attenuated by either miR-195 over-expression or CDK4 silence.
446 Y. Lin et al. / FEBS Letters 586 (2012) 442–447could abrogate Rb phosphorylation and subsequent G1/S transition
by repressing multiple G1/S transition regulators, CDK4 included.
Finally, luciferase assay conﬁrm that miR-195 could speciﬁcally in-
hibit CDK4 by binding to a critical region located on its 3’-UTR.
As a key cell cycle regulator, serine-threonine kinase CDK4 trig-
gers an important cascade of events in G1-phase [28]. It can efﬁ-
ciently catalyze Rb phosphorylation. Thus, CDK4 is regarded as a
‘primary sensor’ for driving cells through the R point, which marks
the entry to a new round of replication. Therefore, CDK4 has been
considered as a desirable target for cancer therapies [28–31]. The
speciﬁc CDK4 know-down with siRNA phenocopied the cell cycle
arrest effect of miR-195 over-expression, which further strength-
ened our ﬁndings that CDK4 is another important mediator of
miR-195-induced cell cycle arrest, besides the validated E2F3,
CDK6, Cyclin D1 [16] and Cyclin E [27].
In summary, our study conﬁrms that miR-195 is frequently
down-regulated in bladder cancer. miR-195, as a tumor suppressorRb phosphorylation status. (A) Real-time RT-PCR analysis indicated that the relative
Western blot analysis of CDK4 protein and Rb phosphorylation status. b-actin was
ssion. siCDK4 effectively silenced CDK4. The phosphorylation of Rb on Ser780 and
Fig. 6. Validation of CDK4 as the direct targets of miR-195. (A) A schematic of the
MicroCosmTargets Version 5 (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/
targets/v5/) predicted seed region in the 3’ UTRs of CDK4 was shown, as well as the
mutated sequences used in this study. (B) T24 cellswere co transfectedwith 50 nMof
eithermiR-195 or NC and 200 ng pmirGLODual-LuciferasemiRNA Target Expression
Vector comprising Wt or Mut 3’-UTR of CDK4. The relative ﬁreﬂy luciferase activity
normalized with renilla luciferase was measured 48 h after transfection. miR-195
signiﬁcant suppressed the ﬁreﬂy luciferase activity of construct with Wt 3’-UTR of
CDK4. (⁄P < 0.05)
Y. Lin et al. / FEBS Letters 586 (2012) 442–447 447in bladder cancer cells, can induce G1-phase arrest by targeting the
novel target CDK4. Our experimental data suggests an important
role of miR-195 in bladder tumorigenesis and implicates restora-
tion of miR-195 could be a potential therapeutic strategy for blad-
der cancer therapy.
Acknowledgements
We acknowledge all members of the Key Lab of Multi-Organ
Transplantation of Health Ministry and Zhejiang University Labora-
toryAnimalCenter for their support. Thisworkwas supportedby the
National Natural Science Foundation of China (Nos.30973466,
30801370) and the Natural Science Foundation of Zhejiang Province
(No. Z2090356).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2012.01.027.
References
[1] Ploeg, M., Aben, K.K. and Kiemeney, L.A. (2009) The present and future burden
of urinary bladder cancer in the world. World J. Urol. 27, 289–293.
[2] Yang, L., Parkin, D.M., Li, L.D., Chen, Y.D. and Bray, F. (2004) Estimation and
projection of the national proﬁle of cancer mortality in China: 1991–2005. Br.
J. Cancer 90, 2157–2166.
[3] Kim, W.J. and Bae, S.C. (2008) Molecular biomarkers in urothelial bladder
cancer. Cancer Sci. 99, 646–652.[4] Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and
function. Cell 116, 281–297.
[5] Bartel, D.P. (2009) MicroRNAs: target recognition and regulatory functions.
Cell 136, 215–233.
[6] Palmero, E.I., de Campos, S.G., Campos, M., de Souza, N.C., Guerreiro, I.D.,
Carvalho, A.L. and Marques, M.M. (2011) Mechanisms and role of microRNA
deregulation in cancer onset and progression. Genet. Mol. Biol. 34, 363–370.
[7] Zhao, L., Chen, X., Cao, Y. (2011). New role of microRNA: carcinogenesis and
clinical application in cancer. Acta Biochim Biophys Sin (Shanghai).
[8] Gottardo, F. et al. (2007) Micro-RNA proﬁling in kidney and bladder cancers.
Urol. Oncol. 25, 387–392.
[9] Lin, T., Dong, W., Huang, J., Pan, Q., Fan, X., Zhang, C. and Huang, L. (2009)
MicroRNA-143 as a tumor suppressor for bladder cancer. J. Urol. 181,
1372–1380.
[10] Ostenfeld, M.S. et al. (2010) MiR-145 induces caspase-dependent and -
independent cell death in urothelial cancer cell lines with targeting of an
expression signature present in Ta bladder tumors. Oncogene 29, 1073–1084.
[11] Ichimi, T. et al. (2009) Identiﬁcation of novel microRNA targets based on
microRNA signatures in bladder cancer. Int. J. Cancer 125, 345–352.
[12] Han, Y. et al. (2011) MicroRNA expression signatures of bladder cancer
revealed by deep sequencing. PLoS One 6, e18286.
[13] Porkka, K.P., Pfeiffer, M.J., Waltering, K.K., Vessella, R.L., Tammela, T.L. and
Visakorpi, T. (2007) MicroRNA expression proﬁling in prostate cancer. Cancer
Res. 67, 6130–6135.
[14] Zanette, D.L., Rivadavia, F., Molfetta, G.A., Barbuzano, F.G., Proto-Siqueira, R.,
Silva-Jr, W.A., Falcao, R.P. and Zago, M.A. (2007) MiRNA expression proﬁles in
chronic lymphocytic and acute lymphocytic leukemia. Braz. J. Med. Biol. Res.
40, 1435–1440.
[15] Wong, T.S., Liu, X.B., Wong, B.Y., Ng, R.W., Yuen, A.P. and Wei, W.I. (2008)
Mature miR-184 as potential oncogenic microRNA of squamous cell
carcinoma of tongue. Clin. Cancer Res. 14, 2588–2592.
[16] Xu, T., Zhu, Y., Xiong, Y., Ge, Y.Y., Yun, J.P. and Zhuang, S.M. (2009) MicroRNA-
195 suppresses tumorigenicity and regulates G1/S transition of human
hepatocellular carcinoma cells. Hepatology 50, 113–121.
[17] Liu, L., Chen, L., Xu, Y., Li, R. and Du, X. (2010) MicroRNA-195 promotes
apoptosis and suppresses tumorigenicity of human colorectal cancer cells.
Biochem. Biophys. Res. Commun. 400, 236–240.
[18] Molenaar, J.J., Ebus, M.E., Koster, J., van Sluis, P., van Noesel, C.J., Versteeg, R.
and Caron, H.N. (2008) Cyclin D1 and CDK4 activity contribute to the
undifferentiated phenotype in neuroblastoma. Cancer Res. 68, 2599–2609.
[19] Boehm, T., Folkman, J., Browder, T. and O’Reilly, M.S. (1997) Antiangiogenic
therapy of experimental cancer does not induce acquired drug resistance.
Nature 390, 404–407.
[20] Prasad, S.M., Decastro, G.J. and Steinberg, G.D. (2011) Urothelial carcinoma of
the bladder: deﬁnition, treatment and future efforts. Nat. Rev. Urol..
[21] Farazi, T.A., Spitzer, J.I., Morozov, P. and Tuschl, T. (2011) MiRNAs in human
cancer. J. Pathol. 223, 102–115.
[22] Osaki, M., Takeshita, F. and Ochiya, T. (2008) MicroRNAs as biomarkers and
therapeutic drugs in human cancer. Biomarkers 13, 658–670.
[23] Sotillo, E. and Thomas-Tikhonenko, A. (2011) Shielding the messenger (RNA):
microRNA-based anticancer therapies. Pharmacol. Ther. 131, 18–32.
[24] Catto, J.W. et al. (2011) MicroRNA in prostate, bladder, and kidney cancer: a
systematic review. Eur. Urol. 59, 671–681.
[25] Wszolek, M.F. et al. (2009) A MicroRNA expression proﬁle deﬁning the
invasive bladder tumor phenotype. Urol. Oncol..
[26] Wang, G., Zhang, H., He, H., Tong, W., Wang, B., Liao, G., Chen, Z. and Du, C.
(2010) Up-regulation of microRNA in bladder tumor tissue is not common. Int.
Urol. Nephrol. 42, 95–102.
[27] Sekiya, Y., Ogawa, T., Iizuka, M., Yoshizato, K., Ikeda, K. and Kawada, N. (2011)
Down-regulation of cyclin E1 expression by microRNA-195 accounts for
interferon-beta-induced inhibition of hepatic stellate cell proliferation. J. Cell
Physiol. 226, 2535–2542.
[28] Graf, F., Koehler, L., Kniess, T., Wuest, F., Mosch, B. and Pietzsch, J. (2009) Cell
cycle regulating kinase Cdk4 as a potential target for tumor cell treatment and
tumor imaging. J. Oncol. 2009, 106378.
[29] Zou, X., Ray, D., Aziyu, A., Christov, K., Boiko, A.D., Gudkov, A.V. and Kiyokawa,
H. (2002) Cdk4 disruption renders primary mouse cells resistant to oncogenic
transformation, leading to Arf/p53-independent senescence. Genes Dev. 16,
2923–2934.
[30] Miliani de Marval, P.L., Macias, E., Rounbehler, R., Sicinski, P., Kiyokawa, H.,
Johnson, D.G., Conti, C.J. and Rodriguez-Puebla, M.L. (2004) Lack of cyclin-
dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues.
Mol. Cell Biol. 24, 7538–7547.
[31] Wang, X., Yu, B., Wu, Y., Lee, R.J. and Lee, L.J. (2011) Efﬁcient down-regulation
of CDK4 by novel lipid nanoparticle-mediated siRNA delivery. Anticancer Res.
31, 1619–1626.
